Pembrolizumab + DEBIO1143
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma of the Pancreas
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Trial Timeline
Sep 15, 2019 → Jun 8, 2022
NCT ID
NCT03871959About Pembrolizumab + DEBIO1143
Pembrolizumab + DEBIO1143 is a phase 1 stage product being developed by Merck for Adenocarcinoma of the Pancreas. The current trial status is completed. This product is registered under clinical trial identifier NCT03871959. Target conditions include Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03871959 | Phase 1 | Completed |
Competing Products
20 competing products in Adenocarcinoma of the Pancreas